TYRA net incomeQ2 2026-$45.56M
TYRA net income was -$45.56M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$28.10M a year earlier. For the full fiscal 2025 it was -$119.95M, compared with -$86.48M in fiscal 2024.
Tyra Biosciences Inc. (TYRA) financials
For the twelve months ended Jun 30, 2026, Tyra Biosciences Inc. reported -$148.56M of net income.
- Net income, TTM
- -$148.56M
- Free cash flow, TTM
- -$109.90M
- EPS, diluted, TTM
- -$2.40
- Cash
- $73.83M
- Market cap
- $1.45B
FY2020FY2025
FY2020FY2025
TYRA revenue and earnings growth
TYRA EPSQ2 2026-$0.69
TYRA diluted EPS was -$0.69 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.47 a year earlier. For the full fiscal 2025 it was -$2.01, compared with -$1.51 in fiscal 2024.
TYRA free cash flowQ2 2026-$31.14M
TYRA free cash flow was -$31.14M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$23.71M a year earlier. For the full fiscal 2025 it was -$95.28M, compared with -$70.44M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $102.93M | $80.08M | $62.52M | $43.01M | $20.64M | $7.20M |
| Selling, general and admin | $29.83M | $24.10M | $17.43M | $15.92M | $5.65M | $2.09M |
| Operating income | -$132.76M | -$104.18M | -$79.94M | -$58.93M | -$26.29M | -$9.30M |
| Income tax | $0 | $0 | $0 | $2.0K | $1.0K | $1.0K |
| Net income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -$26.29M | -$9.34M |
| EPS, basic | -$2.01 | -$1.51 | -$1.62 | -$1.32 | -$1.91 | -$6.05 |
| EPS, diluted | -$2.01 | -$1.51 | -$1.62 | -$1.32 | -$1.91 | -$6.05 |
| Diluted shares | 59.6M | 57.2M | 42.7M | 41.9M | 13.8M | 1.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $77.39M | $92.97M | $59.01M | $252.21M | $302.43M | $15.47M |
| Current assets | $265.45M | $347.46M | $211.67M | $257.29M | $304.06M | $15.28M |
| Total assets | $282.61M | $363.56M | $225.86M | $266.18M | $306.70M | $16.01M |
| Current liabilities | $18.09M | $14.59M | $15.33M | $5.70M | $3.62M | $1.86M |
| Total liabilities | $23.43M | $20.41M | $21.59M | $8.35M | $4.96M | $2.00M |
| Shareholders' equity | $259.18M | $343.15M | $204.26M | $257.83M | $301.74M | -$13.64M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$95.14M | -$69.77M | -$50.14M | -$50.28M | -$23.75M | -$7.76M |
| Capital expenditures | $141.0K | $664.0K | $770.0K | $559.0K | $661.0K | $312.0K |
| Free cash flow | -$95.28M | -$70.44M | -$50.91M | -$50.84M | -$24.41M | -$8.07M |
| Investing cash flow | $72.46M | -$98.40M | -$144.60M | -$559.0K | -$645.0K | -$312.0K |
| Financing cash flow | $8.10M | $202.14M | $1.54M | $632.0K | $311.35M | $23.43M |
| Stock-based compensation | $28.01M | $22.80M | $13.53M | $10.59M | $2.89M | $439.0K |
| Depreciation and amortization | $546.0K | $519.0K | $357.0K | $296.0K | $140.0K | $47.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $39.20M | $33.47M | $28.19M | $25.47M | $24.31M | $24.96M | $22.18M | $22.70M | $18.00M | $17.20M | $20.68M | $19.27M |
| Selling, general and admin | $9.81M | $8.53M | $8.33M | $7.47M | $7.14M | $6.89M | $7.56M | $5.91M | $5.54M | $5.12M | $4.96M | $4.69M |
| Operating income | -$49.00M | -$42.00M | -$36.52M | -$32.94M | -$31.45M | -$31.85M | -$29.74M | -$28.60M | -$23.53M | -$22.32M | -$25.63M | -$23.96M |
| Net income | -$45.56M | -$39.30M | -$33.83M | -$29.87M | -$28.10M | -$28.15M | -$25.57M | -$24.02M | -$18.70M | -$18.19M | -$22.83M | -$21.15M |
| EPS, basic | -$0.69 | -$0.64 | -$0.57 | -$0.50 | -$0.47 | -$0.47 | -$0.43 | -$0.41 | -$0.32 | -$0.35 | -$0.54 | -$0.49 |
| EPS, diluted | -$0.69 | -$0.64 | -$0.57 | -$0.50 | -$0.47 | -$0.47 | -$0.43 | -$0.41 | -$0.32 | -$0.35 | -$0.54 | -$0.49 |
| Diluted shares | 66.0M | 61.7M | - | 59.7M | 59.6M | 59.3M | - | 58.9M | 58.7M | 52.2M | - | 42.9M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $73.83M | $84.95M | $77.39M | $61.95M | $98.49M | $100.72M | $92.97M | $103.89M | $99.49M | $254.37M | $59.01M | $215.65M |
| Current assets | $366.97M | $394.61M | $265.45M | $281.22M | $302.15M | $324.57M | $347.46M | $365.61M | $378.57M | $390.78M | $211.67M | $224.63M |
| Total assets | $383.36M | $412.04M | $282.61M | $301.85M | $321.50M | $343.48M | $363.56M | $380.59M | $392.46M | $404.74M | $225.86M | $238.36M |
| Current liabilities | $24.62M | $19.26M | $18.09M | $15.88M | $13.77M | $14.25M | $14.59M | $12.37M | $10.38M | $8.72M | $15.33M | $10.15M |
| Total liabilities | $29.70M | $24.46M | $23.43M | $21.34M | $19.35M | $19.94M | $20.41M | $18.30M | $16.42M | $14.86M | $21.59M | $16.19M |
| Shareholders' equity | $353.66M | $387.57M | $259.18M | $280.51M | $302.15M | $323.53M | $343.15M | $362.29M | $376.04M | $389.88M | $204.26M | $222.17M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.08M | -$32.57M | -$23.62M | -$22.38M | -$23.68M | -$25.46M | -$19.59M | -$17.90M | -$10.26M | -$22.03M | -$13.53M | -$17.14M |
| Capital expenditures | $66.0K | $88.0K | $57.0K | $39.0K | $31.0K | $14.0K | $6.0K | $52.0K | $470.0K | $136.0K | $603.0K | $83.0K |
| Free cash flow | -$31.14M | -$32.66M | -$23.68M | -$22.42M | -$23.71M | -$25.47M | -$19.60M | -$17.95M | -$10.73M | -$22.16M | -$14.13M | -$17.23M |
| Investing cash flow | $17.85M | -$120.24M | $34.38M | -$14.81M | $20.87M | $32.03M | $6.96M | $21.56M | -$144.99M | $18.07M | -$144.44M | -$83.0K |
| Financing cash flow | $2.10M | $160.38M | $4.68M | $647.0K | $583.0K | $2.19M | $706.0K | $743.0K | $373.0K | $200.31M | $324.0K | $467.0K |
| Stock-based compensation | $10.23M | $7.85M | $7.63M | $7.58M | $6.38M | $6.42M | $6.70M | $7.57M | $4.41M | $4.12M | $4.19M | $4.38M |
| Depreciation and amortization | $138.0K | $138.0K | $132.0K | $131.0K | $140.0K | $143.0K | $144.0K | $127.0K | $126.0K | $122.0K | $102.0K | $83.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 14.91 | 20.49 | 14.67 | 17.71 | 21.94 | 22.78 | 23.81 | 29.55 | 36.46 | 44.83 | 13.80 | 22.14 |
Source: XBRL data Tyra Biosciences Inc. files with the SEC, latest filing dated Aug 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
TYRA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TYRA | - | - | -$148.56M | - | $1.45B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
TYRA FAQ
6 questionsIs TYRA profitable?
No. Tyra Biosciences Inc. reported a net loss of $148.56M for the twelve months ended Jun 30, 2026.How much cash and debt does TYRA have?
Tyra Biosciences Inc. reported $73.83M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is TYRA free cash flow?
Tyra Biosciences Inc. generated -$109.90M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$109.65M less capital expenditures.What is TYRA earnings per share?
Diluted earnings per share were -$2.40 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did TYRA last report financial results?
The latest statements here come from Tyra Biosciences Inc.'s 10-Q filed on Aug 4, 2026, covering the period ended Jun 30, 2026.Where does this TYRA financial data come from?
Quantisnow builds these statements from the structured XBRL data Tyra Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.